Quarterly ResultAug 11, 2026, 10:36 AM
Microbot Medical Q2 Revenue +100%; Customer Growth, LIBERTY System Expansion
AI Summary
Microbot Medical Inc. announced the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026. The company reported significant growth, with revenue increasing by over 100% compared to the previous quarter, driven by the Full Market Release of its LIBERTY Endovascular Robotic System and expanded customer adoption. Key achievements include market expansion into new states, increased utilization among existing customers, a partnership with Lovell Government Services, and regulatory clearance in Israel.
Key Highlights
- Revenue increased by more than 100% over the prior fiscal quarter.
- Commenced Full Market Release of the LIBERTY System in April 2026.
- Expanded LIBERTY System adoption to new health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania.
- Entered agreement with Lovell Government Services to access over 2,000 federal healthcare facilities.
- Broadened sales footprint to eight territories, targeting 12 by year-end.
- Israel granted marketing clearance for the LIBERTY System, making it the first outside the U.S.
- Awarded the 2026 Innovative Start-Up Award from Surgical Robotics Technology.
- Increased procedure volume and number of hospital sites using the LIBERTY System.
Price Impact
More from MBOT